Adjuvant therapy of biliary tract cancers
Adjuvant therapy of biliary tract cancers
Biliary tract cancers (BTCs) are rare and heterogeneous malignant tumours including cholangiocarcinoma and gallbladder cancer. They are very aggressive, often refractory to chemotherapy and associated with an overall poor prognosis. Surgical resection remains the only potentially curative treatment option but less than 35% present with resectable disease. Adjuvant treatments have been widely used but until recently, supportive data were limited to non-randomised, non-controlled retrospective studies. Recent evidence from the BILCAP trial has established adjuvant capecitabine as the standard of care. But there are still unanswered questions as to the role of adjuvant therapy. Further prospective data and translational research with reproducible evidence of clinical benefit are needed. In this review of adjuvant therapy in resectable BTCs, we will summarise the latest evidence setting current treatment standards and highlight future prospects.
adjuvant treatment, biliary tract cancer, cholangiocarcinoma, gallbladder cancer, neoadjuvant therapy
Kefas, Joanna
535bba5c-a22f-42e7-9959-e299a442b74a
Bridgewater, John
a7c51f93-a80e-4b89-828f-34f477259d5c
Vogel, Arndt
bf5269fc-2341-49ae-9dca-6c18891032d6
Stein, Alexander
accef19e-35b2-4619-8748-221184adbacb
Primrose, John
d85f3b28-24c6-475f-955b-ec457a3f9185
28 March 2023
Kefas, Joanna
535bba5c-a22f-42e7-9959-e299a442b74a
Bridgewater, John
a7c51f93-a80e-4b89-828f-34f477259d5c
Vogel, Arndt
bf5269fc-2341-49ae-9dca-6c18891032d6
Stein, Alexander
accef19e-35b2-4619-8748-221184adbacb
Primrose, John
d85f3b28-24c6-475f-955b-ec457a3f9185
Kefas, Joanna, Bridgewater, John, Vogel, Arndt, Stein, Alexander and Primrose, John
(2023)
Adjuvant therapy of biliary tract cancers.
Therapeutic Advances in Medical Oncology, 15.
(doi:10.1177/17588359231163785).
Abstract
Biliary tract cancers (BTCs) are rare and heterogeneous malignant tumours including cholangiocarcinoma and gallbladder cancer. They are very aggressive, often refractory to chemotherapy and associated with an overall poor prognosis. Surgical resection remains the only potentially curative treatment option but less than 35% present with resectable disease. Adjuvant treatments have been widely used but until recently, supportive data were limited to non-randomised, non-controlled retrospective studies. Recent evidence from the BILCAP trial has established adjuvant capecitabine as the standard of care. But there are still unanswered questions as to the role of adjuvant therapy. Further prospective data and translational research with reproducible evidence of clinical benefit are needed. In this review of adjuvant therapy in resectable BTCs, we will summarise the latest evidence setting current treatment standards and highlight future prospects.
Text
Adj therapy biliary tract cancers TAMO Mar 23
- Version of Record
More information
Accepted/In Press date: 27 February 2023
e-pub ahead of print date: 28 March 2023
Published date: 28 March 2023
Additional Information:
Publisher Copyright:
© The Author(s), 2023.
Keywords:
adjuvant treatment, biliary tract cancer, cholangiocarcinoma, gallbladder cancer, neoadjuvant therapy
Identifiers
Local EPrints ID: 477512
URI: http://eprints.soton.ac.uk/id/eprint/477512
ISSN: 1758-8359
PURE UUID: ad43cb7f-6388-4a99-90a8-4e11ad04acd4
Catalogue record
Date deposited: 07 Jun 2023 17:02
Last modified: 18 Mar 2024 02:40
Export record
Altmetrics
Contributors
Author:
Joanna Kefas
Author:
John Bridgewater
Author:
Arndt Vogel
Author:
Alexander Stein
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
